Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05831358 · ClinicalTrials.gov registry record · NA
Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program
A NA study of Multiple Myeloma and Smoldering Multiple Myeloma, sponsored by Case Comprehensive Cancer Center.
- Active
- Registry status
- NA
- Development phase
- 201
- Enrollment target
- 1
- Study location
NCT05831358: Active NA study of Multiple Myeloma and Smoldering Multiple Myeloma, sponsored by Case Comprehensive Cancer Center.
NCT05831358 is a NA study of Multiple Myeloma and Smoldering Multiple Myeloma that is active but no longer recruiting, run by Case Comprehensive Cancer Center. The registered enrollment target is 201 participants, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05831358, a NA study of Multiple Myeloma and Smoldering Multiple Myeloma, is active but no longer recruiting, sponsored by Case Comprehensive Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 201 participants
- Enrollment target
- 1
- Study location
Study Summary
This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This study also aims to gauge the current and general understanding of MM. This study seeks to recruit participants in the pilot screening program to promote early detection. Participants who have abnormal results will receive patient navigation for further diagnostics and testing.
Primary Outcome
The goal is to leverage the existing model of community outreach and patient navigation to study the MM screening program, including community reception, screening program methods, reasons patients decided to participate, reasons patients declined participation, and participant views and attitudes. This will be measured by the overall community reception of this screening being offered.
Conditions Studied
Interventions
- OTHER Multiple Myeloma M-Protein Analysis
- OTHER Multiple Myeloma Knowledge Questionnaires
Study Locations (1)
Ohio
- Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center - Cleveland
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2023-06-16 |
| Est. Completion | 2026-07 |
| Phase | NA |
What the registry record for NCT05831358 still lists
NCT05831358 is an interventional study that assigns participants to a tested intervention. The registered 201 participants enrollment target is mid-sized for trials with a published cap, below the 546-participant average among 438 other Multiple Myeloma trials with a reported enrollment target (63% lower).
The record links to 3 conditions, with Multiple Myeloma appearing as the primary indexed condition, and to 2 interventions - of which Multiple Myeloma M-Protein Analysis is the first listed.
NCT05831358 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT05831358 about?
NCT05831358 is a clinical study titled "Early Detection of Multiple Myeloma to Fight Cancer Disparities: A Screening and Patient Navigation Program". This project will pilot the expansion of the existing Taussig Outreach Program's community outreach and patient navigation model to study the multiple myeloma (MM) screening program. This involves analyzing community reception, screening program methods, reasons patients decided to participate, reas...
What is the current status of trial NCT05831358?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 201 participants. The study started on 2023-06-16. Estimated completion is 2026-07.
What conditions does trial NCT05831358 study?
This clinical trial studies the following conditions: Multiple Myeloma, Smoldering Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance.
What interventions are being tested in trial NCT05831358?
The interventions under investigation include: Multiple Myeloma M-Protein Analysis (OTHER), Multiple Myeloma Knowledge Questionnaires (OTHER).
Who is sponsoring clinical trial NCT05831358?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05831358 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Multiple Myeloma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05831358's enrollment target sits among peer trials
201 109th of 438 higher than 330 of 438 other Multiple Myeloma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Multiple Myeloma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of a Plant-Based Diet and Dietary Supplements in People With Smoldering Multiple Myeloma (SMM) or Monoclonal Gammopathy of Undetermined Significance (MGUS)
RECRUITING · NA
-
An AI-Generated, Personalized Question Prompt List Intervention for Patients With Hematologic Cancers
RECRUITING · NA
-
Prehabilitation Exercise Training in Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
RECRUITING · NA
-
Understanding the Mechanisms of Clonal and Non-clonal Cytopenia Following CAR-T Therapy for Multiple Myeloma or CD19+ Lymphoproliferative Disorder (LPD)
RECRUITING · NA
-
Study Using Prebiotics to Improve Gut Microbiome Diversity After Autologous Stem Cell Transplantation
RECRUITING · NA
-
Prehabilitation Feasibility Among Older Adults Undergoing Transplantation
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04422652 · 201 participants · Phase 2
Combination of Novel Therapies for CKD Comorbid Depression
- NCT05327114 · 201 participants · Phase 2
Efficacy and Safety Study of Nipocalimab for Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
- NCT06099769 · 201 participants · Phase 2
A Study of Enzalutamide, Enzalutamide in Combination With Mifepristone, or Chemotherapy in People With Metastatic Breast Cancer
- NCT06274528 · 201 participants · Phase 2
DORA and LP in Alzheimer's Disease Biomarkers
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI